Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.
Study identifier:D2820C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
-
Medical condition
Colorectal Neoplasms
Phase
Phase 2
Healthy volunteers
No
Study drug
ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin
Sex
All
Actual Enrollment
180
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Sept 2003
Primary Completion Date: 01 Feb 2004
Study Completion Date: 01 Feb 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
